Anti-hepatitis C virus threshold value in predicting hepatitis C virus viremia in hemodialysis patients

抗丙型肝炎病毒阈值在预测血液透析患者丙型肝炎病毒血症中的应用

阅读:1

Abstract

OBJECTIVE: Hepatitis C virus prevalence is higher in hemodialysis patients than in the general population. It is recommended that patients who are detected to be anti-hepatitis C virus seropositive should be dialyzed in separate machines. In patients requiring urgent hemodialysis treatment, anti-hepatitis C virus seropositivity may cause confusion and delay in dialysis sessions. METHODS: The aim of the study was to determine the most appropriate signal-to-cutoff value to predict hepatitis C virus viremia in hemodialysis patients and to evaluate the effect of genotype differences. A total of 12,280 anti-hepatitis C virus results from hemodialysis patients between 2021 and 2024 were examined. RESULTS: The mean age of 563 patients included in the study was 57 years, and 330 (58.6%) were male. Of the 563 patients, 68 (12.07%) were true hepatitis C virus patients. The mean age of hepatitis C virus-ribonucleic acid(+) patients was higher than that of the hepatitis C virus-ribonucleic acid(-) group (p<0.018). Anti-hepatitis C virus signal-to-cutoff value was >1 in all true hepatitis C virus patients. Hepatitis C virus-ribonucleic acid was accepted as the gold standard to determine the best threshold value in receiver operating characteristic curve analysis, and the most appropriate signal-to-cutoff value was found to be 2.23. Sensitivity was 98.5%, specificity was 87.1%, positive predictive value was 51.2%, and negative predictive value was 99.8%. 49 (85.96%) of the patients were identified as genotype(-1; the most common subtype was genotype-1b (n=43). CONCLUSION: Anti-hepatitis C virus negativity is a reliable result in hemodialysis patients. If anti-hepatitis C virus signal-to-cutoff ≥2.23 is detected, confirmation by direct hepatitis C virus-ribonucleic acid testing is recommended. In hemodialysis patients with anti-hepatitis C virus signal-to-cutoff values between 1 and 2.23, false positivity should be considered first, and confirmatory tests should be performed if anti-hepatitis C virus is reactive in a second sample.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。